Trump Administration Botches Delivery Of Potential Coronavirus Treatment
It was reported on Thursday by the Washington Post that the Trump administration had vials of medicine that could treat coronavirus delivered to the wrong hospitals. The medicine was the antiviral drug, remdesivir. The drug showed positive signs that it can ease coronavirus symptoms in clinical trials.
The mishap was reported on by Yasmeen Abutaleb, Josh Dawsey, Lena Sun, and Laurie McGinley. The report reads, “The first tranche of 607,000 vials of the antiviral medication remdesivir, donated to the government by drugmaker Gilead Sciences, was distributed in early May — in some cases to the wrong hospitals, to hospitals with no intensive care units and therefore no eligible patients, and to facilities without the needed refrigeration to store it, meaning some had to be returned to the government, said the officials familiar with the distribution effort.”
The report went on to say, “The government’s initial distribution in the first week of May was so problematic that White House coronavirus response coordinator Deborah Birx shared fallout from state health and hospital officials with senior staffers on the task force, according to three senior administration officials. State officials had expressed anger and frustration that the government initially decided which hospitals to send the drug to without consulting them.”
According to the report, the problem was rectified once the problem was discovered. It reads, “Daniel Abazia, director of the pharmacy for Capital Health, a two-hospital system in southern New Jersey, said the confusion that surrounded the initial rollout of remdesivir dissipated as the state took over the allocation. He said the health system has gotten two shipments of the drug and now is in a ‘good position,’ especially since its number of COVID-19 patients is decreasing.”
The report goes onto to note that despite the correction the mishap still caused problems. According to the report, “Doctors said that because the drug is the only approved treatment for COVID-19 patients and in extremely short supply, any delay or reduced availability would be potentially catastrophic.”
We can only hope that a mishap like this doesn’t happen again.